Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT)

Janus Henderson Group PLC cut its position in Applied Therapeutics, Inc. (NASDAQ:APLT) by 99.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,791 shares of the company’s stock after selling 10,505,737 shares during the period. Janus Henderson Group PLC’s holdings in Applied Therapeutics were worth $31,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Propel Bio Management LLC grew its stake in shares of Applied Therapeutics by 46.4% during the fourth quarter. Propel Bio Management LLC now owns 9,615,420 shares of the company’s stock worth $8,233,000 after purchasing an additional 3,047,562 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in Applied Therapeutics by 2,458.3% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company’s stock worth $7,502,000 after buying an additional 8,419,781 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Applied Therapeutics by 2,511.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,420,920 shares of the company’s stock worth $4,642,000 after acquiring an additional 5,213,370 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Applied Therapeutics by 0.7% in the 4th quarter. Deutsche Bank AG now owns 4,468,122 shares of the company’s stock valued at $3,843,000 after acquiring an additional 30,520 shares during the last quarter. Finally, Alyeska Investment Group L.P. increased its holdings in shares of Applied Therapeutics by 175.8% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,707,497 shares of the company’s stock valued at $2,318,000 after acquiring an additional 1,725,824 shares during the last quarter. 98.31% of the stock is currently owned by institutional investors and hedge funds.

Applied Therapeutics Trading Down 0.0%

APLT stock opened at $0.41 on Monday. The company has a market capitalization of $58.03 million, a P/E ratio of -0.25 and a beta of 2.00. The business has a 50 day simple moving average of $0.42 and a 200-day simple moving average of $1.55. Applied Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $10.62.

Applied Therapeutics (NASDAQ:APLT) last issued its quarterly earnings data on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.61 million. Research analysts predict that Applied Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $1.50 price target on shares of Applied Therapeutics in a report on Wednesday, May 14th. Wall Street Zen upgraded shares of Applied Therapeutics to a “sell” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Applied Therapeutics presently has an average rating of “Hold” and a consensus target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.